China Universal Asset Management Co. Ltd. Purchases 2,321 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

China Universal Asset Management Co. Ltd. raised its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 63.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,966 shares of the company’s stock after purchasing an additional 2,321 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in HUTCHMED were worth $117,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in shares of HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after purchasing an additional 564 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in HUTCHMED by 9.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock valued at $226,000 after acquiring an additional 1,168 shares during the period. Blue Trust Inc. boosted its holdings in shares of HUTCHMED by 638.2% during the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after acquiring an additional 3,057 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of HUTCHMED by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company’s stock worth $1,060,000 after acquiring an additional 4,877 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in shares of HUTCHMED by 70.5% during the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock valued at $304,000 after purchasing an additional 7,515 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Stock Down 5.0 %

Shares of NASDAQ HCM opened at $18.00 on Friday. HUTCHMED has a 12-month low of $11.93 and a 12-month high of $21.92. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The firm has a 50 day moving average of $18.61 and a 200 day moving average of $18.63.

Analyst Ratings Changes

Several brokerages recently issued reports on HCM. The Goldman Sachs Group raised their target price on shares of HUTCHMED from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Thursday, July 18th.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.